# FDC (NSE: FDC) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/FDC · Pivot · prices to 22 Oct 2026

FDC (NSE: FDC) closed at ₹339.20 on 22 Oct 2026, down 0.24% on the day. With a market capitalisation of ₹5,523 Cr, it ranks 751st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.

Its return on equity was 11.7% in FY25. Over the past year the share price has fallen 22.1%. Its 52-week range is ₹312.95 (30 Mar 2026) to ₹473.60 (3 Nov 2025); the last close is 28.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹668 Cr (+3.0% year on year) and net profit ₹132 Cr (+9.2%), on a consolidated basis. Promoters held 69.66% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹339.20 |
| Market cap | ₹5,523 Cr |
| ROE | 11.7% (FY25) |
| ROCE | 15.4% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹473.60 (3 Nov 2025) |
| 52-week low | ₹312.95 (30 Mar 2026) |
| 1-year return | −22.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹668 Cr | +3.0% | ₹132 Cr | +9.2% | ₹8.14 |
| Q4 FY26 | ₹585 Cr | +18.9% | ₹103 Cr | +167.4% | ₹6.35 |
| Q3 FY26 | ₹465 Cr | +0.1% | ₹28 Cr | −23.6% | ₹1.74 |
| Q2 FY26 | ₹473 Cr | −7.9% | ₹28 Cr | −60.6% | ₹1.75 |
| Q1 FY26 | ₹648 Cr | +1.6% | ₹121 Cr | +1.9% | ₹7.45 |
| Q4 FY25 | ₹492 Cr | +6.5% | ₹39 Cr | −16.4% | ₹2.38 |
| Q3 FY25 | ₹464 Cr | +1.3% | ₹37 Cr | −53.2% | ₹2.28 |
| Q2 FY25 | ₹514 Cr | +5.7% | ₹72 Cr | +3.2% | ₹4.43 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2,108 Cr | ₹267 Cr |
| FY24 | ₹1,943 Cr | ₹305 Cr |
| FY23 | ₹1,784 Cr | ₹194 Cr |
| FY22 | ₹1,528 Cr | ₹216 Cr |
| FY21 | ₹1,333 Cr | ₹301 Cr |
| FY20 | ₹1,344 Cr | ₹241 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 69.66%
- Foreign institutions: 1.40%
- Domestic institutions: 6.31%
- Non-institutions: 22.63%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |
| [Nephrocare Health Services](https://app.pivotnow.in/stock/NEPHROPLUS) | ₹599.90 | ₹6,019 Cr | 74.1 | — |
| [Sun Pharma Advanced Research Company](https://app.pivotnow.in/stock/SPARC) | ₹176.82 | ₹5,738 Cr | 3.7 | — |
| [Senores Pharmaceuticals](https://app.pivotnow.in/stock/SENORES) | ₹1,233.30 | ₹5,680 Cr | 46.7 | — |
| [Innova Captab](https://app.pivotnow.in/stock/INNOVACAP) | ₹983.60 | ₹5,629 Cr | 40 | — |
| [IOL Chemicals and Pharmaceuticals](https://app.pivotnow.in/stock/IOLCP) | ₹173.27 | ₹5,086 Cr | 36.9 | — |

## Questions and answers

### What is the share price of FDC today?

FDC (NSE: FDC) last closed at ₹339.20 on 22 Oct 2026. Its 52-week high is ₹473.60 and its 52-week low is ₹312.95.

### What is the market cap of FDC?

FDC's market capitalisation is ₹5,523 Cr (₹5,523 Cr) at the 22 Oct 2026 close, ranking 751st among the NSE companies Pivot tracks.

### What is the ROE and ROCE of FDC?

Return on equity was 11.7% in FY25 and return on capital employed was 15.4% in FY25 (consolidated figures).

### Is FDC a debt-free company?

FDC is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were FDC's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), FDC reported revenue of ₹668 Cr, +3.0% year on year, and net profit of ₹132 Cr, +9.2% year on year.

### How has FDC stock performed over the last year?

FDC's share price has fallen 22.1% over the past year, −17.5% over three months and −6.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of FDC?

As of 30 Jun 2026: promoters 69.66%, foreign institutions 1.40%, domestic institutions 6.31%, non-institutions 22.63%.

### Who are FDC's competitors?

The listed Pharma & Healthcare companies closest to FDC by market cap are Kovai Medical Center & Hospital, Nephrocare Health Services, Sun Pharma Advanced Research Company, Senores Pharmaceuticals, Innova Captab and IOL Chemicals and Pharmaceuticals.

### Is FDC a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out FDC's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FDC against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.